Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc portion of human IgG1. It binds with high affinity to CD80 and CD86 on antigen-presenting cells, specifically blocking the CD28-mediated costimulatory signal required for T-cell activation. Abatacept is widely used to investigate rheumatoid arthritis, autoimmune responses, and immune dysregulation caused by LRBA deficiency.

Animal Model: Male Lewis rats (6-9 weeks old) with weights of 150-175 g. Dosage: 10 mg/kg (i.v.), 20 mg/kg (s.c. single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29. Administration: i.v. or s.c. [2]

Monoclonal

Unconjugated